Improvements in patient-reported outcomes with apremilast, an oral phosphodiesterase 4 inhibitor, in the treatment of moderate to severe psoriasis: results from a phase IIb randomized, controlled study

BACKGROUND: Apremilast, a specific inhibitor of phosphodiesterase 4, modulates pro-inflammatory and anti-inflammatory cytokine production. OBJECTIVES: Apremilast’s effect on patient-reported outcomes (PROs) in patients with moderate to severe psoriasis was evaluated in a phase IIb randomized, contro...

Descripción completa

Detalles Bibliográficos
Autores principales: Strand, Vibeke, Fiorentino, David, Hu, ChiaChi, Day, Robert M, Stevens, Randall M, Papp, Kim A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2013
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3661377/
https://www.ncbi.nlm.nih.gov/pubmed/23663752
http://dx.doi.org/10.1186/1477-7525-11-82

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3661377/
https://www.ncbi.nlm.nih.gov/pubmed/23663752
http://dx.doi.org/10.1186/1477-7525-11-82

Ejemplares similares